Vivo Opportunity Fund, L.P. 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Mar 25, 2019
Insider Transaction Report
Form 4
Vivo Capital VIII, LLC
10% Owner
Transactions
- Sale
Common Stock
2019-03-20$22.25/sh−292,609$6,510,550→ 2,732,730 total(indirect: See Footnote) - Sale
Common Stock
2019-03-20$22.25/sh−40,407$899,056→ 377,355 total(indirect: See Footnote) - Sale
Common Stock
2019-03-20$22.25/sh−83,984$1,868,644→ 210,373 total(indirect: See Footnote)
Footnotes (5)
- [F1]These securities are held of record by Vivo Capital Fund VIII, L.P. ("VCF").
- [F2]These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. ("VCSF").
- [F3]These securities are held of record by Vivo Opportunity Fund, L.P. ("VOF").
- [F4]Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Albert Cha, Edgar Engleman, Chen Yu and Shan Fu, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.
- [F5]Vivo Opportunity, LLC is the general partner of VOF. The voting members of Vivo Opportunity, LLC are Frank Kung, Albert Cha, Shan Fu, Gaurav Aggarwal and Michael Chang, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes